Cullinan Therapeutics Inc
CGEM
View Detailed Chart
12.230USD
+0.380+3.21%
Close 02/06, 16:00（ET）Quotes delayed by 15 min
722.50MMarket Cap
LossP/E TTM
Intraday
1m
30m
1h
D
W
M
D
Today
+3.21%
5 Days
+2.26%
1 Month
+20.37%
6 Months
+55.20%
Year to Date
+18.16%
1 Year
+18.16%
View Detailed Chart
TradingKey Stock Score of Cullinan Therapeutics Inc
Currency: USD Updated: 2026-02-06Key Insights
Cullinan Therapeutics Inc's fundamentals are relatively weak, with an industry-leading ESG disclosure.and its growth potential is high.Its valuation is considered fairly valued, ranking 37 out of 392 in the Biotechnology & Medical Research industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Strong Buy, with the highest price target at 32.27.In the medium term, the stock price is expected to trend up.Despite a good stock market performance and strong technicals over the past month, the fundamentals don't support the current trend.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Cullinan Therapeutics Inc's Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Media Coverage
Last 24 hours
Coverage Level
Very Low
Very High
Neutral
Cullinan Therapeutics Inc Highlights
StrengthsRisks
Cullinan Therapeutics, Inc. is a biopharmaceutical company. It has built a diversified portfolio of clinical-stage assets that inhibit key drivers of disease or harness the immune system to eliminate diseased cells in autoimmune diseases and cancer. Its portfolio includes a range of modalities. Its pipeline includes CLN-978, CLN-619, Zipalertinib (CLN-081/TAS6417), CLN-049, and CLN-617. CLN-978 is a CD19xCD3 T cell engager being developed for autoimmune diseases. CLN-619 is a monoclonal antibody that stabilizes expression of MICA/B on the tumor cell surface to promote tumor cell lysis mediated by cytotoxic innate and adaptive immune cells. Zipalertinib (CLN-081/TAS6417) is an orally available small-molecule, irreversible epidermal growth factor receptor inhibitor. CLN-049 is a FLT3xCD3 T cell engaging bispecific antibody. CLN-617 is a fusion protein combining two potent antitumor cytokines, interleukin-2 and interleukin-12 with tumor retention domains for the treatment of solid tumors.
Fairly Valued
The company’s latest PE is -3.32, at a medium 3-year percentile range.
Institutional Buying
The latest institutional holdings are 64.92M shares, increasing 4.72% quarter-over-quarter.
Held by HOTCHKIS & WILEY
Star Investor HOTCHKIS & WILEY holds 1.76K shares of this stock.
Analyst Rating
Based on
12
analysts
Strong Buy
Current Rating
32.273
Target Price
+172.34%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
Cullinan Therapeutics Inc News
More news coming soon, stay tuned...
Financial Indicators
EPS
Relevant data have not been disclosed by the company yet.
Total revenue
Relevant data have not been disclosed by the company yet.
Cullinan Therapeutics Inc Info
Cullinan Therapeutics, Inc. is a biopharmaceutical company. It has built a diversified portfolio of clinical-stage assets that inhibit key drivers of disease or harness the immune system to eliminate diseased cells in autoimmune diseases and cancer. Its portfolio includes a range of modalities. Its pipeline includes CLN-978, CLN-619, Zipalertinib (CLN-081/TAS6417), CLN-049, and CLN-617. CLN-978 is a CD19xCD3 T cell engager being developed for autoimmune diseases. CLN-619 is a monoclonal antibody that stabilizes expression of MICA/B on the tumor cell surface to promote tumor cell lysis mediated by cytotoxic innate and adaptive immune cells. Zipalertinib (CLN-081/TAS6417) is an orally available small-molecule, irreversible epidermal growth factor receptor inhibitor. CLN-049 is a FLT3xCD3 T cell engaging bispecific antibody. CLN-617 is a fusion protein combining two potent antitumor cytokines, interleukin-2 and interleukin-12 with tumor retention domains for the treatment of solid tumors.
Ticker SymbolCGEM
CompanyCullinan Therapeutics Inc
CEOAhmed (Nadim)
Websitehttps://cullinantherapeutics.com/
Related Instruments
+3.66%
+3.17%
+0.93%
+1.99%
+1.78%
+1.60%
-0.95%
+4.49%
+2.10%
+10.00%
+2.72%
+4.15%
+1.81%
+4.17%
+0.72%
+1.06%
+2.46%
0.00%
+0.53%
+0.56%Popular Symbols
278.120
+2.210 (+0.80%)
185.410
+13.530 (+7.87%)
69169.970
-800.160 (-1.14%)
282.580
+22.390 (+8.61%)
2044.040
-7.690 (-0.38%)
411.110
+13.900 (+3.50%)
4952.980
+142.360 (+2.96%)
63.303
+0.206 (+0.33%)
1.182
+0.004 (+0.35%)
157.098
+0.057 (+0.04%)
